European Archives - Page 4 of 1486 - European Medical Journal

New Classification Criteria in SpA: EULAR 2026

Classification criteria and recommendations for the diagnosis and clinical management of spondyloarthritis have been updated and were presented at EULAR 2026.

Improving the Patient Experience in Rheumatology: EULAR 2026

Researchers have highlighted, at EULAR 2026, different pathways through which the rheumatology patient’s experience can be enhanced.

New Life-Extending Drug for Women with Ovarian Cancer

A new ovarian cancer drug, mirvetuximab soravtansine, has been approved on the NHS, offering improved survival and better tolerability for patients with treatment-resistant ovarian cancer through a targeted antibody-drug approach.

Early Neonatal Infection Linked to Cerebral Palsy Risk

A cohort study of over one million children has found that neonatal infection significantly increases risk of cerebral palsy, especially severe motor subtypes and nonambulatory outcomes.

ADCs Show Strong Activity in Advanced Urothelial Carcinoma

Antibody-drug conjugates including enfortumab vedotin and disitamab vedotin demonstrate strong efficacy in advanced urothelial carcinoma across trials and real-world settings.

Robotic and Endoscopic Mastectomy Shows Comparable Outcomes

Study finds robotic and endoscopic single-incision nipple-sparing mastectomy techniques deliver comparable surgical outcomes, complication rates, and patient satisfaction. Learn More.

Effects of Calorie Restriction on Kidney Donors

Exploratory findings suggest that organ protection is promoted through calorie restriction in living kidney donors.

Semaglutide Boosts QoL in T2D and CKD - EMJ

Semaglutide Improves QoL in Patients with Diabetes and CKD: ERA 2026

New FLOW trial data show semaglutide improves health-related quality of life in people with Type 2 diabetes and chronic kidney disease.

New Insights in Gout Management: EULAR 2026

Urate-lowering therapy in a treat-to-target strategy can foster higher remission rates in patients with gout, according to new data presented at EULAR 2026.

CAR-T Cell Therapies in Refractory RMD: EULAR 2026

CAR-T cell therapies prove promising in treatment-refractory rheumatic and musculoskeletal diseases, according to new research presented at EULAR 2026.